Production (Stage)
Cellectar Biosciences, Inc.
CLRB
$0.3822
-$0.031-7.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.97M | 6.54M | 7.83M | 6.36M | 4.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.40M | 12.74M | 13.33M | 13.70M | 12.00M |
| Operating Income | -6.40M | -12.74M | -13.33M | -13.70M | -12.00M |
| Income Before Tax | -6.60M | -2.29M | -14.66M | -919.40K | -26.64M |
| Income Tax Expenses | -- | 66.00K | -- | -- | -- |
| Earnings from Continuing Operations | -6.60M | -2.36M | -14.66M | -919.40K | -26.64M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.60M | -2.36M | -14.66M | -919.40K | -26.64M |
| EBIT | -6.40M | -12.74M | -13.33M | -13.70M | -12.00M |
| EBITDA | -6.34M | -12.68M | -13.26M | -13.64M | -11.91M |
| EPS Basic | -0.14 | -0.06 | -0.37 | -0.03 | -0.91 |
| Normalized Basic EPS | -0.09 | -0.03 | -0.23 | -0.02 | -0.57 |
| EPS Diluted | -0.14 | -0.06 | -0.40 | -0.18 | -0.91 |
| Normalized Diluted EPS | -0.09 | -0.03 | -0.23 | -0.02 | -0.57 |
| Average Basic Shares Outstanding | 46.08M | 41.94M | 39.34M | 35.82M | 29.35M |
| Average Diluted Shares Outstanding | 46.08M | 41.94M | 39.79M | 37.45M | 29.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |